Journal September 25, 2026 6 min read

Common misconceptions about the blood-brain barrier

The blood-brain barrier is a dynamic, regulated interface, not a wall. This page examines what the research literature actually reports about its permeability, its receptors, and the models used to study it.

peptides-pro Editorial

The blood-brain barrier (BBB) is the collective name for the specialised properties of the brain microvascular endothelium, together with the tight junctions between its cells, the basement membrane, pericytes, and the astrocytic end-feet that invest the vessels. It is also referred to as the neurovascular unit when the surrounding cellular components are included, and the term "blood-brain barrier permeability" is used in the clinical literature as a measurable variable rather than a fixed property. The evidence block for this page does not supply a sequence, formula, or molecular weight for the barrier itself, because the barrier is a tissue-level structure rather than a single molecule; the identifiers that appear in the sources are those of the compounds and proteins studied in relation to it.

The work summarised below centres on receptor-mediated transcytosis (RMT) as the principal route by which large molecules are moved across the barrier, with the transferrin receptor (TfR) and the insulin-like growth factor 1 receptor (IGF1R) named as the BBB-side proteins in that system [4].

Research Studies

Dual targeting of TfR and intra-brain proteins for antibody delivery and retention

A 2025 study proposed combining binding to intra-brain proteins with binding to BBB proteins as a way of improving both delivery and retention of therapeutic antibodies in the brain [4]. The intra-brain targets named were myelin oligodendrocyte glycoprotein (MOG), cell adhesion molecule 3, and chondroitin sulfate proteoglycan 5; the BBB-side targets named were TfR and IGF1R [4]. The rationale given was that TfR shuttle systems achieve delivery but are cleared from the brain rapidly, and that binding to intra-brain proteins could sustain retention [4]. This is a preclinical strategy paper; the findings are not human dosing information.

Transcutaneous auricular vagal nerve stimulation and radiation necrosis-related cerebral edema

A multi-centre, randomised, blinded trial is evaluating transcutaneous auricular vagal nerve stimulation (taVNS) in patients with radiation necrosis-related cerebral edema [1]. Participants are assigned to a treatment arm or a sham arm, and both arms undergo imaging plus tissue and blood collection for assessment of changes in the area of contrast enhancement and cerebral edema, inflammatory markers, and markers of blood-brain barrier permeability [1]. The design treats BBB permeability as an outcome measure rather than an assumption, which is relevant to the misconception that barrier status is static.

Cerebrolysin after extended-window endovascular thrombectomy

A multicentre randomised clinical trial is testing whether Cerebrolysin, given after successful extended-window endovascular thrombectomy, reduces brain tissue injury and supports recovery [3]. The background states that thrombectomy can benefit selected patients treated 6 to 24 hours after stroke onset, but that some patients remain disabled even when the blocked artery is reopened, and that ongoing injury to brain tissue, small blood vessels, and the blood-brain barrier may contribute to incomplete recovery [3]. The population is patients with acute ischaemic stroke from large-artery occlusion.

Circulating placental growth factor in IDH-wildtype glioblastoma

A prospective observational study examined circulating placental growth factor (PlGF) in 54 patients with IDH-wildtype glioblastoma, with plasma samples collected at diagnosis and at recurrence and analysed using a multiplex panel of angiogenesis mediators [6]. The stated premise is that angiogenesis in glioblastoma is multifactorial and that blood-brain barrier disruption enables detection of circulating mediators [6]. This is a human observational study; it reports associations with disease characteristics and outcomes, not a mechanism of barrier opening that can be generalised.

Nanoparticles and senescent brain endothelial cells

Polymeric nanoparticles loaded with the senolytic agent Navitoclax were designed to selectively eliminate senescent cells, on the basis that brain endothelial cell senescence is a key factor in age-related BBB impairment [8]. The nanoparticles are taken up by both proliferative and senescent brain endothelial cells but are degraded only in the senescent cells, owing to senescence-associated beta-galactosidase, releasing the drug to induce cell death [8]. The reported result is effective and selective elimination of senescent cells in the model used [8]. This is preclinical work.

Low-dose ketamine, astrocyte mitochondria, and NMDAR antagonism

A review of the ketamine literature notes that antidepressant efficacy has classically been attributed to noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) on the neuronal postsynaptic membrane, reducing excessive calcium influx through the NMDAR channel, and that recent evidence suggests additional physiological changes [5]. The review frames this in terms of astrocyte mitochondrial preconditioning and the upregulation and efflux of adenosine, humanin, and melatonin [5]. The material is a literature synthesis; it does not establish a clinical protocol.

Circadian rhythm disruption and Alzheimer's disease

A narrative review synthesises literature on how circadian dysfunction may contribute to Alzheimer's disease pathogenesis, biomarker profiles, and treatment response [7]. Mechanistic studies cited in that review suggest interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis, with circadian-regulated pathways including BMAL1-SIRT1 and NF-kappaB-NLRP3 named [7]. The population is patients with Alzheimer's disease and relevant model systems; the review is a synthesis, not primary data.

Protein-energy wasting and anabolic resistance in advanced CKD

A framework paper proposes a "sensitize-then-feed" model for protein-energy wasting in advanced chronic kidney disease, arguing that a subset of uraemic patients shows a nutritional paradox in which standard nutritional interventions, including oral supplements and intradialytic parenteral nutrition, are often insufficient because of systemic anabolic resistance [2]. The relevance to barrier discussion is indirect: it concerns a barrier to nutritional therapy rather than the blood-brain barrier, and is included here only to mark the distinction between the two uses of the word barrier.

Study	Model or population	Barrier-related measure
taVNS trial [1]	Patients with radiation necrosis-related cerebral edema	Markers of BBB permeability; contrast enhancement area
Cerebrolysin trial [3]	Patients with acute ischaemic stroke, 6-24 h window	Ongoing injury to BBB cited as contributor to incomplete recovery
PlGF study [6]	54 patients with IDH-wildtype glioblastoma	BBB disruption as premise for detecting circulating mediators
Nanoparticle senolytic study [8]	Brain endothelial cell senescence model	Selective elimination of senescent BECs
Dual-targeting antibody study [4]	Preclinical RMT system	TfR and IGF1R binding; intra-brain protein binding for retention

Quantification methods across BBB models

Two semi-automated image-analysis pipelines have been presented to replace manual scoring of BBB integrity from fluorescence microscopy, addressing the limited reproducibility of subjective scoring and categorical classification [9]. The work concerns measurement rather than barrier biology, and is relevant because many apparent disagreements in the literature trace to how integrity was scored.

Acute-phase SPARC and delayed cerebral ischemia after subarachnoid haemorrhage

Elevated acute-phase plasma SPARC levels have been reported to precede the development of angiographic vasospasm and delayed cerebral ischemia in severe aneurysmal subarachnoid haemorrhage [10]. SPARC is described as a matricellular protein involved in neurovascular injury and blood-brain barrier dysfunction [10]. This is a clinical association study.

If you are reading this for personal health reasons

The materials described on this page are supplied for laboratory research use only, and we do not provide dosing, administration, or medical guidance of any kind. Nothing here is a recommendation for or against any compound in any person. Anyone considering a compound for themselves should speak to a licensed clinician.